Adult human mesenchymal stem cells ( DrugBank: Adult human mesenchymal stem cells )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	1
96	クローン病	4

85. 特発性間質性肺炎

臨床試験数 : 598 / 薬物数 : 435 - (DrugBank : 116) / 標的遺伝子数 : 100 - 標的パスウェイ数 : 210

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02013700 (ClinicalTrials.gov)	November 13, 2013	2/12/2013	Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)	A Phase I, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Idiopathic Pulmonary Fibrosis	Idiopathic Pulmonary Fibrosis (IPF)	Biological: Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs);Biological: matched placebo	Joshua M Hare	The Lester And Sue Smith Foundation;The Emmes Company, LLC	Terminated	40 Years	90 Years	All	9	Phase 1	United States

96. クローン病

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01233960 (ClinicalTrials.gov)	November 29, 2010	2/11/2010	Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease	A Multicenter, Open-label Study to Evaluate the Safety of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects Who Have Received Previous Remestemcel-L Induction Treatment for Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	73	Phase 3	United States;Australia;New Zealand
2	NCT00543374 (ClinicalTrials.gov)	September 17, 2007	11/10/2007	Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Durability and Retreatment Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Maintenance and Re-induction of Clinical Benefit and Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: Placebo;Drug: PROCHYMAL adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	98	Phase 3	United States;Canada
3	NCT00482092 (ClinicalTrials.gov)	September 17, 2007	30/5/2007	Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease	A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease	Crohn's Disease	Drug: Prochymal®;Drug: Placebo	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	330	Phase 3	United States;Australia;Canada;New Zealand
4	NCT00294112 (ClinicalTrials.gov)	March 13, 2006	17/2/2006	Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease	A Phase II, Open-label, Randomized Study to Evaluate the Safety and Efficacy of PROCHYMAL™ IBD (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Treatment of Subjects Experiencing Moderate-to-severe Crohn's Disease That is Refractory to Steroids and Immune Suppressants	Crohn's Disease	Drug: Prochymal™ adult human mesenchymal stem cells;Drug: adult human mesenchymal stem cells	Mesoblast, Inc.	NULL	Completed	18 Years	70 Years	All	10	Phase 2	United States